# A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

> **NCT06942572** · PHASE1,PHASE2 · RECRUITING · sponsor: **Splice Bio** · enrollment: 57 (estimated)

## Conditions studied

- Stargardt Disease
- Stargardt Macular Degeneration
- Stargardt Macular Dystrophy

## Interventions

- **GENETIC:** SB-007

## Key facts

- **NCT ID:** NCT06942572
- **Lead sponsor:** Splice Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-11
- **Primary completion:** 2028-10-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06942572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06942572, "A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06942572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*